$Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience$

Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

<p>Abstract</p> <p>Background</p> <p>The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxici...

Full description

Bibliographic Details
Main Authors:	Nakano Kazuhiko, Ohta Shigeyuki, Komatsu Kenji, Kubo Taro, Nukui Akinori, Suzuki Kazumi, Kurokawa Shinsuke, Kobayashi Minoru, Morita Tatsuo
Format:	Article
Language:	English
Published:	BMC 2012-02-01
Series:	BMC Urology
Online Access:	http://www.biomedcentral.com/1471-2490/12/3

Similar Items

Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
by: Tatsuo Morita
Published: (2010-04-01)

Estramustine-Induced Suicidal Erythrocyte Death
by: Rosi Bissinger, et al.
Published: (2013-11-01)

Reversal of multidrug resistance in bladder cancer cell lines with estramustine and its derivatives
by: Jennings, Andrew Melvin
Published: (2005)

Estramustine phosphate in the treatment of hormone escape prostatic carcinoma - a 3 year follow-up
by: Altaf H Syed, et al.
Published: (2003-01-01)

Estramustine Phosphate Inhibits TGF-β-Induced Mouse Macrophage Migration and Urokinase-Type Plasminogen Activator Production
by: Sonja S. Mojsilovic, et al.
Published: (2018-01-01)

A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
by: Carducci Michael, et al.
Published: (2010-02-01)

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
by: Narita Shintaro, et al.
Published: (2012-01-01)

Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.
by: Lixian Zhong, et al.
Published: (2013-01-01)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Filippo Francini, et al.
Published: (2011-01-01)

Involvement of magnitude of ambient temperature change in nonspecific effect in perceived placebo effect on lower urinary tract symptoms: study on switching of naftopidil in patients with benign prostatic hyperplasia
by: Morita T, et al.
Published: (2013-04-01)

Life-threatening acute acalculous cholecystitis in a patient with renal cell carcinoma treated by sunitinib: a case report
by: Nakano Kazuhiko, et al.
Published: (2012-02-01)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Hui-Li Wong, et al.
Published: (2015-06-01)

Clinical outcomes in castration resistant prostate cancer patients treated with docetaxel
by: Shian-Shiang Wang, et al.
Published: (2016-06-01)

Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel.
by: Takashi Kawahara, et al.
Published: (2012-01-01)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
by: Manuel Caitano Maia, et al.
Published: (2017-03-01)

Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells
by: Irin Tanaudommongkon, et al.
Published: (2020-07-01)

Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert
by: Amelia Altavilla, et al.
Published: (2012-06-01)

Weekly-docetaxel chemotherapy for Taiwanese patients withmetastatic castrate-resistant prostate cancer
by: Cheng-Li Kao, et al.
Published: (2015-06-01)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
by: Li Q, et al.
Published: (2019-12-01)

Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
by: ShengYu Ku, et al.
Published: (2014-01-01)

Docetaxel (Tautax) in the treatment of hormone-refractory prostate cancer
by: I. G. Rusakov, et al.
Published: (2020-02-01)

Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma
by: Hugo Ford, et al.
Published: (2015-07-01)

Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α-Blockers
by: Minoru Kobayashi, et al.
Published: (2017-09-01)

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients
by: DUAN Liqun, et al.
Published: (2019-09-01)

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
by: Keith L. Davis, et al.

Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer
by: Yuan-Chi Shen, et al.
Published: (2016-09-01)

PSA flare in metastatic castration-resistant prostate cancer patients treated with abiraterone or docetaxel
by: Hui-Ying Liu, et al.
Published: (2016-06-01)

Weekly docetaxel in an elderly patient with refractory classic Kaposi sarcoma
by: Rongbo Lin
Published: (2016-06-01)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
by: Victoria J Sinibaldi
Published: (2008-01-01)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
by: Masayoshi Zaitsu, et al.
Published: (2012-01-01)

EXPERIENCE WITH OCTREOTIDE IN PATIENTS WITH CASTRATION REFRACTORY PROSTATE CANCER
by: D. I. Ganov, et al.
Published: (2014-07-01)

EXPERIENCE WITH OCTREOTIDE IN PATIENTS WITH CASTRATION REFRACTORY PROSTATE CANCER
by: D. I. Ganov, et al.
Published: (2014-07-01)

Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Seiichi Kato, et al.
Published: (2021-01-01)

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
by: Seonggyu Byeon, et al.
Published: (2020-11-01)

Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer.
by: Sha Zhu, et al.
Published: (2014-01-01)

Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy
by: Ayako Ohtaka, et al.
Published: (2019-03-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-04-01)

Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
by: Sartor A Oliver
Published: (2011-04-01)

A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer
by: Eric Zhuang, et al.
Published: (2021-11-01)

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
by: Jie Xu, et al.
Published: (2018-10-01)